Seven Fleet Capital Management LP
Seven Fleet Capital Management LP reported 96 US-listed holdings worth $605.9 million in its 13F for the quarter ended 30 June 2026, filed 17 August 2026. Its largest: CG Oncology Inc. (22.1%), Tango Therapeutics Inc. (15.8%) and Revolution Medicines, Inc. (7.5%). Against the quarter before, it opened 24 positions, added to 43, trimmed 22 and sold out of 43.
Reported holdings$605.9M+90.4% on Q1 2026
Positions96-19 on Q1 2026
The largest ten65.1%of its reported holdings
Latest 13FQ2 2026filed 17 August 2026
OpenedAdded to
The 14 largest of its 96 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 24Added 43Held 7Trimmed 22Sold out 43
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 24
- Mirum Pharmaceuticals Inc. MIRM$12.9 million
- Veradermics Inc MANE$9.8 million
- Editas Medicine, Inc. EDIT$4.3 million
- Sutro Biopharma Inc. STRO$3.8 million
- Ascendis Pharma A/s ASND$3.2 million
- Sagimet Biosciences Inc. SGMT$3.1 million
- Praxis Precision Medicines I PRAX$2.5 million
- Relmada Therapeutics Inc. RLMD$2.4 million
and 16 more in the table below
Added to 43
- CG Oncology Inc. CGON+1.8 million shares · +2390%
- Tango Therapeutics Inc. TNGX+2.7 million shares · +543%
- Revolution Medicines, Inc. RVMD+161,237 shares · +200%
- Pharvaris N V PHVS+601,770 shares · +348%
- Assembly Biosciences Inc. ASMB+377,000 shares · +671%
- Avalo Therapeutics Inc. AVTX+556,946 shares · +260%
- Enliven Therapeutics Inc. ELVN+201,356 shares · +123%
- Abivax SA ABVX+68,282 shares · +159%
and 35 more in the table below
Trimmed 22
- Agios Pharmaceuticals Inc. AGIO-152,647 shares · -73%
- Vaxcyte Inc. PCVX-78,650 shares · -73%
- Ideaya Biosciences Inc. IDYA-48,418 shares · -56%
- Relay Therapeutics Inc. RLAY-79,516 shares · -31%
- Silence Therapeutics PLC SLN-96,652 shares · -62%
- Krystal Biotech, Inc. KRYS-2,542 shares · -59%
- Compass Therapeutics Inc. CMPX-283,906 shares · -55%
- Corbus Pharmaceuticals Hldgs CRBP-64,255 shares · -75%
and 14 more in the table below
Sold out of 43
- CG Oncology Inc.$97.4 million last quarter
- Tyra Biosciences Inc. TYRA$7.5 million last quarter
- Tango Therapeutics Inc.$6.3 million last quarter
- Avalo Therapeutics Inc.$5.4 million last quarter
- Minerva Neurosciences Inc.$5.4 million last quarter
- Pharvaris N V$4.1 million last quarter
- Soleno Therapeutics Inc. SLNO$3.9 million last quarter
- Enliven Therapeutics Inc.$3.7 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| CG Oncology Inc. CGON | 1.9M | $134.0 million | 22.12% | +1.8M |
| Tango Therapeutics Inc. TNGX | 3.2M | $95.7 million | 15.79% | +2.7M |
| Revolution Medicines, Inc. RVMD | 242.0K | $45.3 million | 7.48% | +161.2K |
| Pharvaris N V PHVS | 774.5K | $26.8 million | 4.42% | +601.8K |
| Liquidia Corp. LQDA | 256.6K | $20.5 million | 3.38% | +68.7K |
| Enliven Therapeutics Inc. ELVN | 365.4K | $18.5 million | 3.06% | +201.4K |
| Abivax SA ABVX | 111.3K | $14.8 million | 2.45% | +68.3K |
| Avalo Therapeutics Inc. AVTX | 770.8K | $14.2 million | 2.35% | +556.9K |
| Mirum Pharmaceuticals Inc. MIRM | 110.4K | $12.9 million | 2.13% | new |
| Assembly Biosciences Inc. ASMB | 433.1K | $11.9 million | 1.96% | +377.0K |
| Century Therapeutics Inc. IPSC | 4.3M | $10.7 million | 1.76% | +1.4M |
| Cytokinetics Inc. CYTK | 118.2K | $10.1 million | 1.66% | +57.0K |
| Taysha Gene Therapies Inc. TSHA | 1.5M | $9.9 million | 1.64% | +878.7K |
| Veradermics Inc MANE | 80.0K | $9.8 million | 1.62% | new |
| Arrivent Biopharma Inc. AVBP | 246.6K | $8.6 million | 1.41% | +196.4K |
| Tarsus Pharmaceuticals Inc. TARS | 117.1K | $7.9 million | 1.31% | +97.3K |
| Xencor Inc. XNCR | 368.3K | $7.8 million | 1.29% | +288.3K |
| Roivant Sciences Ltd. ROIV | 220.1K | $7.8 million | 1.29% | +92.0K |
| Galecto Inc. DMRA | 284.4K | $7.4 million | 1.22% | +183.2K |
| Axsome Therapeutics Inc. AXSM | 28.8K | $7.1 million | 1.16% | +14.8K |
| Definium Therapeutics Inc. DFTX | 148.6K | $7.0 million | 1.15% | +48.8K |
| Dianthus Therapeutics Inc. DNTH | 64.7K | $6.3 million | 1.04% | +10.5K |
| Cogent Biosciences Inc. COGT | 147.5K | $5.7 million | 0.94% | -1.9K |
| Erasca Inc. ERAS | 308.0K | $5.6 million | 0.93% | +85.5K |
| Protagonist Therapeutics, Inc. PTGX | 45.4K | $5.6 million | 0.92% | +41.4K |
| Minerva Neurosciences Inc. NERV | 1.0M | $5.6 million | 0.92% | +752.9K |
| Editas Medicine, Inc. EDIT | 1.3M | $4.3 million | 0.71% | new |
| Cytomx Therapeutics Inc. CTMX | 1.1M | $4.1 million | 0.67% | +714.0K |
| Eupraxia Pharmaceuticals Inc. EPRX | 610.8K | $4.0 million | 0.67% | +177.3K |
| Sutro Biopharma Inc. STRO | 159.1K | $3.8 million | 0.63% | new |
| Relay Therapeutics Inc. RLAY | 178.2K | $3.3 million | 0.55% | -79.5K |
| Celldex Therapeutics Inc. CLDX | 86.7K | $3.2 million | 0.53% | +57.4K |
| Ascendis Pharma A/s ASND | 11.9K | $3.2 million | 0.52% | new |
| Sagimet Biosciences Inc. SGMT | 403.5K | $3.1 million | 0.51% | new |
| Zai Lab Limited ZLAB | 136.0K | $2.9 million | 0.48% | +58.2K |
| Sab Biotherapeutics Inc. SABS | 736.1K | $2.9 million | 0.47% | +636.1K |
| Madrigal Pharmaceuticals Inc. MDGL | 5.0K | $2.7 million | 0.44% | +1.6K |
| Praxis Precision Medicines I PRAX | 7.5K | $2.5 million | 0.42% | new |
| Relmada Therapeutics Inc. RLMD | 348.3K | $2.4 million | 0.40% | new |
| Agios Pharmaceuticals Inc. AGIO | 56.9K | $2.1 million | 0.35% | -152.6K |
| Xenon Pharmaceuticals Inc. XENE | 33.3K | $2.1 million | 0.34% | new |
| Savara Inc. SVRA | 309.1K | $1.9 million | 0.31% | +13.4K |
| C4 Therapeutics Inc. CCCC | 381.2K | $1.8 million | 0.29% | +324.1K |
| Vaxcyte Inc. PCVX | 29.8K | $1.8 million | 0.29% | -78.7K |
| Celcuity Inc. CELC | 16.3K | $1.7 million | 0.28% | +10.3K |
| Syndax Pharmaceuticals Inc. SNDX | 77.9K | $1.6 million | 0.27% | new |
| Zentalis Pharmaceuticals Inc. ZNTL | 317.6K | $1.5 million | 0.24% | +207.6K |
| Structure Therapeutics Inc. GPCR | 26.8K | $1.4 million | 0.24% | +17.8K |
| Athira Pharma Inc. LONA | 154.2K | $1.4 million | 0.23% | -10.5K |
| Ideaya Biosciences Inc. IDYA | 37.9K | $1.4 million | 0.23% | -48.4K |
| Geron Corp. GERN | 1.1M | $1.4 million | 0.22% | +633.0K |
| Adlai Nortye Ltd ANL | 113.2K | $1.3 million | 0.21% | new |
| Corvus Pharmaceuticals Inc. CRVS | 82.9K | $1.2 million | 0.20% | no change |
| Alkermes plc. ALKS | 23.3K | $1.2 million | 0.20% | -885 |
| Spyre Therapeutics Inc. SYRE | 13.3K | $1.2 million | 0.19% | -6.4K |
| Perspective Therapeutics Inc CATX | 332.6K | $1.1 million | 0.19% | -46.5K |
| Onkure Therapeutics Inc OKUR | 241.0K | $1.1 million | 0.18% | new |
| Summit Therapeutics Inc. SMMT | 73.3K | $1.1 million | 0.18% | new |
| AN2 Therapeutics Inc. ANTX | 208.9K | $1.0 million | 0.17% | +9.2K |
| Contineum Therapeutics Inc. CTNM | 60.5K | $992,267 | 0.16% | +33.5K |
| Trevi Therapeutics Inc. TRVI | 45.6K | $833,430 | 0.14% | +18.4K |
| Voyager Therapeutics Inc. VYGR | 230.4K | $771,860 | 0.13% | +115.2K |
| Inventiva SA IVA | 200.1K | $756,533 | 0.12% | no change |
| Engene Therapeut ENGN | 411.1K | $711,142 | 0.12% | new |
| Larimar Therapeutics Inc. LRMR | 230.9K | $704,309 | 0.12% | -25.7K |
| Inhibikase Therapeutics Inc. IKT | 346.9K | $704,207 | 0.12% | +21.3K |
| Neurogene Inc. NGNE | 22.1K | $693,787 | 0.11% | new |
| iShares Trust IHI | 13.8K | $681,858 | 0.11% | new |
| Silence Therapeutics PLC SLN | 60.1K | $659,975 | 0.11% | -96.7K |
| Krystal Biotech, Inc. KRYS | 1.8K | $659,343 | 0.11% | -2.5K |
| Ocuphire Pharma Inc. IRD | 143.1K | $588,293 | 0.10% | +8.9K |
| Palisade Bio Inc. PALI | 272.2K | $568,906 | 0.09% | +59.1K |
| Evolus Inc. EOLS | 78.1K | $541,716 | 0.09% | no change |
| Unicycive Therapeutics Inc. UNCY | 103.4K | $521,136 | 0.09% | +47.7K |
| Compass Therapeutics Inc. CMPX | 233.1K | $510,415 | 0.08% | -283.9K |
| Biocryst Pharmaceuticals Inc. BCRX | 51.0K | $510,240 | 0.08% | -51.5K |
| Bright Minds Biosciences Inc. DRUG | 6.4K | $448,929 | 0.07% | no change |
| Prothena Corp. PLC PRTA | 43.3K | $423,907 | 0.07% | no change |
| Monte Rosa Therapeutics Inc. GLUE | 16.8K | $406,560 | 0.07% | -5.7K |
| Olema Pharmaceuticals Inc. OLMA | 31.5K | $393,765 | 0.06% | new |
| Milestone Pharmaceuticals Inc. (mist) MIST | 270.2K | $362,112 | 0.06% | -63.1K |
| Entera Bio Ltd ENTX | 191.4K | $338,697 | 0.06% | -14.2K |
| Cue Biopharma Inc. Com CUE | 10.7K | $337,755 | 0.06% | new |
| MBX Biosciences Inc. MBX | 6.0K | $331,200 | 0.05% | new |
| Beam Therapeutics Inc. BEAM | 8.8K | $302,153 | 0.05% | no change |
| AstraZeneca PLC AZN | 1.4K | $265,468 | 0.04% | new |
| Amylyx Pharmaceuticals Inc. AMLX | 14.5K | $261,138 | 0.04% | -2.1K |
| Stoke Therapeutics Inc. STOK | 7.7K | $255,353 | 0.04% | new |
| Viking Therapeutics Inc. VKTX | 7.4K | $251,884 | 0.04% | new |
| Lipocine Inc. New LPCN | 78.8K | $201,836 | 0.03% | -46.1K |
| Corbus Pharmaceuticals Hldgs CRBP | 21.4K | $201,032 | 0.03% | -64.3K |
| Promis Neurosciences Inc. PMN | 10.6K | $139,496 | 0.02% | no change |
| Wave Life Sciences Ltd WVE | 19.0K | $99,812 | 0.02% | new |
| PMV Pharmaceuticals Inc. PMVP | 53.6K | $71,782 | 0.01% | -9.9K |
| Fulcrum Therapeutics Inc. FULC | 18.1K | $66,206 | 0.01% | -20.0K |
| Uniqure NV QURE | 338 | $15,254 | 0.00% | new |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.